Long‐term efficacy of first‐line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials is a research paper published in British Journal of Haematology (2021). On theSindex it has a DataRank of 2.2. It has been cited 64 times, with 59 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.626
From this paper's citation signal
Citation Network Contribution
1.6
From 44 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 59 citers.
National Institutes of Health
Grant: 3U10CA180820-02S3
ECOG-ACRIN Operations Center
Fields of Study
Keywords
Sustainable Development Goals